Use for deferiprone
AssigneeApotex Inc.
InventorsMichael Spino, Antonio Piga
Life of this patent
Estimating the term…
Abstract
A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
Claims50
A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
A method of preventing iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
For use to treat iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
For use to prevent iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
The use of deferiprone or a physiologically acceptable salt thereof for the prevention of the risk of heart disease in patients having iron overload, such as in thalassemia or the like.
The use of deferiprone or a physiologically acceptable salt thereof for the stabilization of the risk of heart disease in patients having iron overload, such as in thalassemia or the like.
The use of deferiprone or a physiologically acceptable salt thereof for the reduction of the risk of heart disease in patients having iron overload, such as in thalassemia or the like.
An effective therapeutic amount of deferiprone or a physiologically acceptable salt thereof for the prevention of the risk of heart disease in patients having iron overload, such as in thalassemia or the like, comprising an effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
An effective therapeutic amount of deferiprone or a physiologically acceptable salt thereof for the stabilization of the risk of heart disease in patients having iron overload, such as in thalassemia or the like comprising an effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
An effective therapeutic amount of deferiprone or a physiologically acceptable salt thereof for the reduction of the risk of heart disease in patients having iron overload, such as in thalassemia or the like comprising an effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
A method of preventing the risk of heart disease in patients having iron overload, such as in thalassemia or the like comprising the administration of a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
A method of stabilizing the risk of heart disease in patients having iron overload, such as in thalassemia or the like comprising the administration of a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
A method of reducing the risk of heart disease in patients having iron overload, such as in thalassemia or the like comprising the administration of a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
The use of deferiprone in the manufacture of a pharmaceutical for preventing the risk of heart disease in patients having iron overload, such as in thalassemia or the like comprising the administration of a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
The use of deferiprone in the manufacture of a pharmaceutical for stabilizing the risk of heart disease in patients having iron overload, such as in thalassemia or the like comprising the administration of a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
The use of deferiprone in the manufacture of a pharmaceutical for reducing the risk of heart disease in patients having iron overload, such as in thalassemia or the like comprising the administration of a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
The use of deferiprone for the prevention, treatment, or reversal of heart disease in a patient having an iron overload condition of the heart comprising administering to the patient a therapeutically effective amount of deferiprone, or a physiologically acceptable salt thereof in order to preferentially reduce the iron stores in the heart in comparison to less critical organs/tissue in the body.
A therapeutically effective amount of deferiprone or physiologically acceptable salt thereof for the prevention, treatment, or reversal of heart disease in patients having an iron overload condition of the heart comprising an effective amount of deferiprone or a physiologically acceptable salt thereof to preferentially reduce the iron stores in the heart in comparison to the iron stores in less critical organs/tissue in the body.
The use of deferiprone or a physiologically acceptable salt thereof in the manufacture of a pharmaceutical for the prevention, treatment or reversal of heart disease in patients having an iron overload condition of the heart comprising a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof to preferentially reduce the iron stores in the heart in comparison to the iron stores in less critical organs/tissue in the body.
The use of deferiprone for the treatment, prevention, or reversal of heart disease in a patient having an iron overload condition of the heart comprising administering to the patent a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof for the direct preferential reduction/removal of iron (for example-intracellular iron) stores in the heart.
The use of deferiprone to prevent/treat/reverse the occurrence of iron-induced cardiac disease in patients with an iron overload condition such as thalassemia or the like, comprising administering to said patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof, wherein deferiprone's efficacy is cardio preferential when compared with its ability to lower total iron stores in the body.
A method of treating/preventing/or reversing heart disease in a patient having an iron overload condition of the heart comprising administering to the patient a therapeutically effective amount of deferiprone, or a physiologically acceptable salt thereof in order to preferentially reduce the iron stores in the heart in comparison to less critical organs/tissue in the body.
A method of treating/preventing/or reversing heart disease in patients having an iron overload condition of the heart comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof to preferentially reduce the iron stores in the heart in comparison to the iron stores in less critical organs/tissue in the body.
A method of treating/preventing/or reversing heart disease in patients having an iron overload condition of the heart comprising a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof to preferentially reduce the iron stores in the heart in comparison to the iron stores in less critical organs/tissue in the body.
A method of treatment, prevention, or reversal of heart disease in a patient having an iron overload condition of the heart comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof for the direct preferential reduction/removal of iron (for example—intracellular iron) stores in the heart.
A method to prevent/treat/reverse the occurrence of iron-induced cardiac disease in patients with an iron overload condition such as thalassemia or the like, comprising administering to said patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof, wherein deferiprone's efficacy is cardio preferential when compared with its ability to lower total iron stores in the body.
The use of any of the previous claims further comprising the active ingredient deferiprone or a physiologically acceptable salt thereof for preventing the risk of heart disease in patients having iron overload.
The use of any of the previous claims further comprising the active ingredient deferiprone or a physiologically acceptable salt thereof for stabilizing the risk of heart disease in patients having iron overload.
The use of any of the previous claims further comprising the active ingredient deferiprone or a physiologically acceptable salt thereof for reducing the risk of heart disease in patients having iron overload.
The method of any of the previous claims further comprising the active ingredient deferiprone or a physiologically acceptable salt thereof for preventing the risk of heart disease in patients having iron overload.
The method of any of the previous claims further comprising the active ingredient deferiprone or a physiologically acceptable salt thereof for stabilizing the risk of heart disease in patients having iron overload.
The method of any of the previous claims further comprising the active ingredient deferiprone or a physiologically acceptable salt thereof for reducing the risk of heart disease in patients having iron overload.
The method of any previous claim further comprising an oral dosage form of deferiprone or a physiologically acceptable salt thereof with other excipients.
The use of any previous claim further comprising an oral dosage form of deferiprone or a physiologically acceptable salt thereof with other excipients.
The method of any previous claim further comprising daily administration of an amount of deferiprone or a physiologically acceptable salt thereof substantially in the range of up to 150 mg/kg to the patient.
The use of any previous claim further comprising daily administration of an amount of deferiprone or a physiologically acceptable salt thereof substantially in the range of up to 150 mg/kg to the patient.
The method of any previous claim further comprising administration of a daily dosage amount of deferiprone or a physiologically acceptable salt thereof substantially in the range of up to 125 mg/kg to the patient.
The use of any previous claim further comprising administration of a daily dosage amount of deferiprone or a physiologically acceptable salt thereof substantially in the range of up to 125 mg/kg to the patient.
The method of any previous claim further comprising administration of a daily dosage amount of deferiprone or a physiologically acceptable salt thereof substantially in the range of 25 mg/kg to 75 mg/kg to the patient.
The use of any previous claim further comprising administration of a daily dosage amount of deferiprone or a physiologically acceptable salt thereof substantially in the range of 25 mg/kg to 75 mg/kg to the patient.
The method of any previous claim wherein deferiprone is administered in a manner selected from the group of intravenously, transdermally, rectally, orally, bucally, or aurally.
The use of any previous claim wherein deferiprone is administered in a manner selected from the group of intravenously, transdermally, rectally, orally, bucally, or aurally.
The method of any previous claim wherein deferiprone is administered orally.
The use of any previous claim wherein deferiprone is administered orally.
The method of any previous claim wherein the dosage form is a sustained release formulation.
The use of any previous claim wherein the dosage form is a sustained release formulation.
The method of any previous claim wherein deferiprone has a cardio preferred/selective function when compared to desferrioxamine or other alternative chelating agents utilized in patients suffering iron overload.
The use of any previous claim wherein deferiprone has a cardio preferred/selective function when compared to desferrioxamine or other alternative chelating agents utilized in patients suffering iron overload.
The method of any previous claim wherein deferiprone is administered in addition to desferrioxamine.
The use of any previous claim wherein deferiprone is administered in addition to desferrioxamine.
Dependencies are inferred from the claim text.